1. Home
  2. FRAF vs TRDA Comparison

FRAF vs TRDA Comparison

Compare FRAF & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Financial Services Corporation

FRAF

Franklin Financial Services Corporation

SELL

Current Price

$71.11

Market Cap

279.0M

Sector

Finance

ML Signal

SELL

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$4.64

Market Cap

275.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRAF
TRDA
Founded
1906
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
279.0M
275.3M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
FRAF
TRDA
Price
$71.11
$4.64
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
★ $19.00
AVG Volume (30 Days)
30.3K
★ 369.7K
Earning Date
10-27-2026
11-09-2026
Dividend Yield
★ 1.95%
N/A
EPS Growth
★ 88.84
N/A
EPS
★ 2.94
N/A
Revenue
N/A
★ $25,421,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$6.58
$87.87
P/E Ratio
$23.85
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$45.00
$4.11
52 Week High
$70.53
$16.45

Technical Indicators

Market Signals
Indicator
FRAF
TRDA
Relative Strength Index (RSI) 81.97 40.38
Support Level $60.62 $4.11
Resistance Level N/A $7.89
Average True Range (ATR) 1.65 0.48
MACD 0.77 0.04
Stochastic Oscillator 86.54 31.68

Price Performance

Historical Comparison
FRAF
TRDA

About FRAF Franklin Financial Services Corporation

Franklin Financial Services Corp is a bank holding company based in the United States. It is engaged in general commercial, retail banking, and trust services normally associated with community banks. It offers a broad range of banking services to businesses, individuals, and governmental entities, which include accepting and maintaining cheques, savings, and time deposit accounts, providing investment and trust services, making loans and providing safe deposit facilities. The bank also performs personal, corporate, pension and fiduciary services through its Investment and Trust Services Department.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: